Understanding PIRA in Multiple Sclerosis and Neurodegeneration

Understanding the clinical determinants of PIRA in multiple sclerosis represents an urgent priority in neuroimmunology. While focal relapses cause episodic inflammatory deficits, progression independent of relapse activity reflects insidious, chronic neuroaxonal degeneration. Epidemiologists observe that multiple sclerosis affects women at triple the rate of men. However, female patients historically demonstrate distinct intervals to primary disability milestones. The exact contribution of female sex hormones to long-term neurodegeneration has remained unresolved. Contemporary disease-modifying therapies effectively suppress focal inflammatory relapses. Nevertheless, these agents demonstrate far more limited efficacy against gradual, non-relapsing functional decline. Consequently, clinicians must recognize systemic biological factors that govern intrinsic neuronal resilience. Recent experimental data reveal that circulating estrogens and progestins modulate microglial activation and astrocytic inflammation. Furthermore, these endocrine messengers directly influence remyelination capacity and neuronal survival. Therefore, evaluating lifetime reproductive milestones helps clinicians anticipate silent progression trajectories far earlier in disease management.

Design and Population of the San Raffaele Cohort Investigation

To evaluate these relationships systematically, researchers at the San Raffaele MS Center conducted a comprehensive cohort investigation. The investigators analyzed 1210 female patients diagnosed with multiple sclerosis between 2019 and 2023. Specifically, clinicians gathered granular reproductive and contraceptive histories using validated environmental questionnaires. The primary study endpoint measured twelve-week confirmed disability progression independent of recent relapses. The authors strictly excluded any disability accrual occurring within thirty days of an acute attack. Furthermore, clinicians systematically monitored neurological function utilizing the Expanded Disability Status Scale over long-term follow-up. To isolate early progression mechanisms, the protocol excluded patients presenting with primary or secondary progressive courses. Multivariable Cox proportional-hazards models evaluated hormone-related factors while adjusting for key clinical confounders. Specifically, the statistical analysis adjusted for age at disease onset, baseline disability score, and disease-modifying therapy use. Overall, forty percent of participants experienced confirmed progression during the extensive observational period.

Prior Oral Contraceptive Use Delays Silent Disability Accrual

The study revealed a profound protective association with prior oral contraceptive exposure. Patients who used oral contraceptives before their multiple sclerosis diagnosis exhibited a twenty-six percent reduction in progression risk. Furthermore, early contraceptive use substantially postponed the chronological emergence of silent functional deterioration. Specifically, the median time to initial progression reached 9.94 years in contraceptive users versus 7.50 years in non-users. This marked difference produced a significant adjusted hazard ratio of 0.74 with tight confidence intervals. Importantly, this protective benefit endured after controlling for baseline disease severity and patient age. Prolonged latency before silent progression indicates that early synthetic hormone exposure confers durable neural resilience. Additionally, exogenous steroids may preserve blood-brain barrier integrity during early pre-symptomatic inflammatory stages. Consequently, pre-diagnostic contraceptive exposure appears to buffer the central nervous system against late-stage neurodegeneration. These compelling observations suggest that contraceptive history offers meaningful prognostic utility.

Impact of Menopause and Pregnancy on Disease Progression

In contrast to oral contraceptives, other reproductive events demonstrated adverse associations with disease progression. For instance, women undergoing menopause prior to their multiple sclerosis diagnosis faced an eighty-two percent higher hazard of rapid progression. Specifically, postmenopausal status at diagnosis significantly shortened the latency period before initial functional worsening occurred. Neurologists recognize that menopause triggers a rapid drop in circulating estrogens and progesterone. Consequently, the abrupt loss of these neurosteroids accelerates chronic neuroaxonal injury and brain atrophy. Similarly, pregnancy preceding multiple sclerosis diagnosis correlated with accelerated disability worsening, showing an adjusted hazard ratio of 1.22. Interestingly, investigators detected no significant correlations with prior induced abortions, menstrual cycle irregularities, or fertility therapies. Thus, major physiological endocrine shifts profoundly alter long-term neurodegenerative risk, whereas transient fluctuations do not. Clinicians should view postmenopausal onset as a clear clinical marker of heightened progressive vulnerability.

Underlying Endocrine and Neurobiological Mechanisms

Translational and pre-clinical research provides robust biological plausibility for these observed clinical differences. Estrogens, particularly 17beta-estradiol and estriol, exert powerful neuroprotective and anti-inflammatory effects in neural tissue. In particular, estrogen receptor signaling suppresses destructive cytokines like tumor necrosis factor-alpha and interleukin-17. Furthermore, estrogens promote protective microglial phenotypes and enhance oligodendrocyte survival during demyelinating stress. Progesterone similarly bolsters mitochondrial energetics, reduces glutamate excitotoxicity, and supports axonal preservation. Therefore, sustained exposure to synthetic hormones via oral contraceptives may reinforce neurological reserves during early adult life. Conversely, ovarian senescence during menopause abruptly removes essential neuroprotective signaling pathways. As a result, microglia shift into chronically reactive states that sustain smoldering, compartmentalized neuroinflammation. Consequently, intersecting hormonal decline and biological aging accelerates progressive neuroaxonal destruction over time. Additionally, estrogen deficiency impairs endogenous remyelination by inhibiting oligodendrocyte progenitor differentiation.

Translating Endocrine Insights into Clinical Neurology Practice

These compelling findings offer practical guidance for modern neurology and women's health practices. First, clinicians should document detailed reproductive histories during baseline patient assessments. Inquiring about past contraceptive exposure, parity, and menopausal timing provides indispensable context for long-term prognosis. Second, female patients transitioning through menopause require intensified surveillance for insidious progression. Because progression independent of relapse often evades routine clinical detection, physicians must deploy sensitive functional assessments. For example, regular timed walking tests, pegboard evaluations, and cognitive screenings detect subtle deterioration effectively. Furthermore, these findings should encourage prospective clinical trials evaluating targeted hormone replacement therapies in progressive cohorts. Neurologists should also consider earlier initiation of high-efficacy disease-modifying therapies in menopausal women. Moreover, multidisciplinary collaboration between neurologists and gynecologists optimizes holistic care across every reproductive phase. Ultimately, integrating endocrine history into routine neurological care improves individualized disease management and long-term outcomes.

How does progression independent of relapse activity differ from standard relapse-associated worsening?

Progression independent of relapse activity represents insidious neurological deterioration that occurs without preceding acute relapses. In contrast, relapse-associated worsening reflects incomplete clinical recovery directly following an inflammatory relapse. Progression independent of relapse activity primarily stems from diffuse, compartmentalized neurodegeneration, microglial activation, and progressive axonal loss rather than focal white matter inflammatory lesions.

Why might early oral contraceptive use provide long-term neuroprotection in multiple sclerosis?

Oral contraceptives deliver steady synthetic estrogen and progesterone levels that exert anti-inflammatory and neuroprotective effects. In experimental models, these steroids promote oligodendrocyte survival, limit neuroaxonal injury, and suppress pro-inflammatory microglial signaling. Consequently, early endocrine exposure may preserve biological reserve and delay the onset of smoldering neurodegenerative processes for nearly a decade.

How should clinicians adjust surveillance for multiple sclerosis patients undergoing menopause?

Clinicians should intensify objective functional monitoring during the menopausal transition, as estrogen withdrawal accelerates non-relapse disease progression. Specifically, neurologists should incorporate serial cognitive assessments, timed walking tests, and upper extremity functional batteries alongside routine MRI. Furthermore, physicians should evaluate lifestyle factors and discuss individualized disease-modifying therapy adjustments to mitigate heightened neurodegenerative risks.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Giordano A et al. Sex hormone-related factors and the risk of PIRA in women with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2025 Jun 12. doi: 10.1136/jnnp-2024-335547. PMID: 40081962.


2. Voskuhl RR, Wang H, Wu TCJ, et al. Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15(1):35-46.


3. Gava G, Bartolomei I, Costantino A, et al. Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis. Fertil Steril. 2014;102(1):116-122.